“Hard-switch” strategy foiled


Plans by a drug company to “hard-switch” patients to a new formulation of one of its old drugs before its patent ran out has been thwarted by a New York federal court.  Actavis who make the Alzheimer’s drug memantine (Namenda) intended to cease distribution of its old drug, effectively forcing patients on to the new ...


Already a member? Login to keep reading


OR
© 2017 the limbic